Bristol Myers Squibb Announces Patient Death in Multiple Sclerosis Clinical Trial
BMY Bristol-Myers Squibb Co
$61.48 -2.41%
View chart & analysis → - 1Bristol Myers Squibb stated that one patient with active relapsing multiple sclerosis died during the Breakfree-2 study.
- 2Bristol Myers Squibb shares fell 2% on Friday.
- 3No other deaths were reported among the 190 Bristol Myers Squibb patients treated in early-stage studies of the broad Zolasel autoimmune disease program.
So what's the key point?
A patient died during a disease treatment study being conducted by Bristol Myers Squibb. The stock price fell 2% following this news.
Source Stocktwits +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.